Profile data is unavailable for this security.
About the company
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
- Revenue in USD (TTM)154.90m
- Net income in USD-20.20m
- Incorporated1987
- Employees128.00
- LocationHeron Therapeutics Inc4242 Campus Point CourtSuite 200, Suite 300CARY 92121United StatesUSA
- Phone+1 (302) 636-5400
- Websitehttps://www.herontx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Editas Medicine Inc | 46.38m | -199.84m | 209.88m | 246.00 | -- | 14.91 | -- | 4.52 | -2.38 | -2.38 | 0.5454 | 0.1443 | 0.1753 | -- | 11.24 | 188,548.80 | -75.51 | -34.19 | -101.13 | -38.43 | -- | -- | -430.84 | -373.02 | -- | -- | 0.8145 | -- | -58.64 | 9.50 | -54.74 | -- | 7.43 | -- |
| Context Therapeutics Inc | 0.00 | -26.44m | 210.40m | 12.00 | -- | 2.88 | -- | -- | -0.2835 | -0.2835 | 0.00 | 0.7964 | 0.00 | -- | -- | 0.00 | -31.94 | -44.73 | -33.64 | -57.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.52 | -- | -- | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -10.27m | 210.77m | 31.00 | -- | 4.50 | -- | -- | -0.0993 | -0.0993 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -65.28 | -46.29 | -73.32 | -48.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 68.95 | -- | -- | -- |
| Ovid Therapeutics Inc | 6.61m | -36.33m | 216.11m | 23.00 | -- | 2.64 | -- | 32.69 | -0.5112 | -0.5112 | 0.093 | 0.6282 | 0.0794 | -- | -- | 287,391.30 | -43.64 | -13.89 | -49.07 | -15.44 | -- | -- | -549.62 | -40.79 | -- | -- | 0.00 | -- | 44.50 | -- | 49.50 | -- | -7.98 | -- |
| Humacyte Inc | 1.57m | -36.97m | 216.16m | 218.00 | -- | -- | -- | 137.59 | -0.2206 | -0.2206 | 0.011 | -0.0299 | 0.0152 | -- | -- | 7,206.42 | -35.84 | -41.46 | -46.28 | -45.37 | 60.53 | -- | -2,353.22 | -8,438.13 | 0.8965 | -- | 1.10 | -- | -- | -- | -34.24 | -- | -28.00 | -- |
| Prenetics Global Ltd | 92.39m | -52.70m | 223.44m | 285.00 | -- | 1.03 | -- | 2.42 | -3.60 | -4.02 | 6.58 | 15.43 | 0.443 | 6.38 | 22.48 | -- | -26.36 | -55.58 | -31.23 | -71.68 | 52.97 | 47.68 | -59.49 | -381.63 | 2.76 | -13.87 | 0.01 | -- | 479.76 | 7.23 | -51.06 | -- | 77.92 | -- |
| Neonc Technologies Holdings Inc | 59.99k | -48.88m | 225.22m | 3.00 | -- | -- | -- | 3,754.29 | -2.59 | -2.59 | 0.0032 | -0.6067 | 0.0176 | -- | -- | -- | -1,431.87 | -- | -- | -- | 33.34 | -- | -81,472.06 | -- | -- | -22.45 | -- | -- | 17.80 | -- | 20.26 | -- | -- | -- |
| Heron Therapeutics Inc | 154.90m | -20.20m | 226.24m | 128.00 | -- | 17.01 | -- | 1.46 | -0.1205 | -0.1205 | 0.8733 | 0.0761 | 0.6335 | 0.5668 | 1.84 | 1,210,188.00 | -8.26 | -41.54 | -13.40 | -61.25 | 73.31 | 60.34 | -13.04 | -88.20 | 1.51 | -0.2662 | 0.9075 | -- | 7.36 | 11.81 | -48.71 | -- | -45.86 | -- |
| CAMP4 Therapeutics Corp | 3.80m | -53.40m | 229.05m | 55.00 | -- | 3.53 | -- | 60.24 | -2.48 | -2.48 | 0.1746 | 1.25 | 0.0706 | -- | 1.81 | 69,127.27 | -99.11 | -- | -121.32 | -- | -- | -- | -1,404.47 | -- | -- | -- | 0.0013 | -- | 86.29 | -- | -5.07 | -- | -- | -- |
| Voyager Therapeutics Inc | 31.32m | -126.78m | 230.74m | 172.00 | -- | 1.05 | -- | 7.37 | -2.17 | -2.17 | 0.5358 | 3.96 | 0.0877 | -- | 2.64 | 182,069.80 | -35.50 | -1.01 | -39.95 | -1.27 | -- | -- | -404.85 | -2.34 | -- | -- | 0.00 | -- | -68.00 | -5.18 | -149.12 | -- | -14.53 | -- |
| Inhibikase Therapeutics Inc | 0.00 | -47.66m | 233.34m | 15.00 | -- | 1.98 | -- | -- | -1.15 | -1.15 | 0.00 | 0.9745 | 0.00 | -- | -- | 0.00 | -113.51 | -56.32 | -131.71 | -65.21 | -- | -- | -- | -1,965.97 | -- | -- | 0.00 | -- | -100.00 | -- | -44.62 | -- | -- | -- |
| Arcturus Therapeutics Holdings Inc | 97.60m | -66.71m | 237.24m | 174.00 | -- | 1.01 | -- | 2.43 | -2.46 | -2.46 | 3.60 | 8.25 | 0.2989 | -- | 5.12 | 560,919.60 | -20.43 | -19.22 | -24.18 | -24.16 | -- | -- | -68.35 | -68.95 | -- | -- | 0.00 | -- | -8.69 | 48.93 | -172.30 | -- | -4.55 | -- |
| Nuvectis Pharma Inc | 0.00 | -28.87m | 239.49m | 13.00 | -- | 12.61 | -- | -- | -1.31 | -1.31 | 0.00 | 0.7171 | 0.00 | -- | -- | 0.00 | -105.10 | -123.50 | -188.03 | -201.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.95 | -- | -- | -- |
| Angion Biomedica Corp | 0.00 | -45.86m | 242.05m | 32.00 | -- | 62.59 | -- | -- | -3.15 | -3.15 | 0.00 | 0.2211 | 0.00 | -- | -- | 0.00 | -137.56 | -106.87 | -179.35 | -289.86 | -- | -- | -- | -778.01 | -- | -302.49 | 0.7181 | -- | -- | -- | -47.46 | -- | -18.50 | -- |
| Alector Inc | 21.05m | -142.93m | 243.90m | 103.00 | -- | 7.96 | -- | 11.59 | -1.39 | -1.39 | 0.2043 | 0.2777 | 0.0553 | -- | -- | 204,320.40 | -37.54 | -18.23 | -50.42 | -22.68 | -- | -- | -679.16 | -100.47 | -- | -- | 0.2402 | -- | -79.07 | -0.0503 | -20.06 | -- | -61.79 | -- |
Data as of Mar 03 2026. Currency figures normalised to Heron Therapeutics Inc's reporting currency: US Dollar USD
57.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rubric Capital Management LPas of 31 Dec 2025 | 30.05m | 16.39% |
| Clearline Capital LPas of 31 Dec 2025 | 12.24m | 6.67% |
| Adage Capital Management LPas of 31 Dec 2025 | 11.19m | 6.10% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 9.32m | 5.08% |
| Velan Capital Investment Management LPas of 30 Jan 2026 | 8.75m | 4.77% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 8.58m | 4.68% |
| Millennium Management LLCas of 31 Dec 2025 | 7.17m | 3.91% |
| Palisade Capital Management LPas of 31 Dec 2025 | 6.33m | 3.45% |
| Tang Capital Management LLCas of 31 Dec 2025 | 6.25m | 3.41% |
| Tejara Capital Ltd.as of 31 Dec 2025 | 5.13m | 2.80% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
